Australian biotech firm Benitec Biopharma (ASX: BLT) has acquired the full rights to the preclinical ddRNAi-based hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture with China-based Biomics Biotechnologies.
Over the past 12 months, Benitec has advanced the program significantly, and based on promising in vitro data, has taken the decision to develop Hepbarna as a solely-owned lead program by acquiring Biomics' share.
Financial terms of termination
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze